| 07/01/22 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 06/01/22 | Notification about results of final buy-back of shares | AQ |
| 30/12/21 | Notification about final share buy-back | AQ |
| 28/12/21 | Correction: Regarding results of a share buy-back offer | AQ |
| 28/12/21 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 31/12/2025 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 31/12/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 18/06/2021 | |
Janis Buks
CHM | Chairman | - | 31/08/2022 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 04/08/21 | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +7.19% | +2.67% | - | - | 148M | ||
| -0.30% | -6.68% | +29.12% | +125.42% | 1,200B | ||
| +1.25% | -5.35% | +33.19% | +80.42% | 651B | ||
| +0.94% | -2.99% | +24.73% | +106.93% | 506B | ||
| -0.60% | -1.95% | +27.26% | +67.32% | 377B | ||
| +0.69% | -9.50% | +40.80% | +30.23% | 330B | ||
| +0.41% | -4.70% | +27.23% | +51.59% | 288B | ||
| +0.81% | -4.08% | -1.74% | +32.71% | 272B | ||
| -0.15% | -6.45% | +29.63% | +64.18% | 236B | ||
| -0.06% | -0.98% | +33.15% | +118.99% | 206B | ||
| Average | +1.05% | -4.76% | +27.04% | +75.31% | 452B | |
| Weighted average by Cap. | +0.40% | -5.19% | +28.03% | +87.49% |
Employees
2,191
Sector
Pharmaceuticals
















